AJI Cover
Frequency: Continuous
ISSN: 1553-619X (Print)
ISSN: 1558-3775 (Online)
Research Notes Open Access

Individualizing Periods of Commercial Exclusivity to Control Pricing for Drugs and Biologics

Callie M. Blase1, Brandon K. Rouault1, Maia B. Zoller1, Joshua V. Luff1, Emma J. Lerch1, Brynn N. Lauterbachq1, Mark A. Brown1, Joachim Storsberg2 and Christian Schmidt2
  • 1 Colorado State University, United States
  • 2 Fraunhofer-Institute for Applied Polymer Research , Germany

Abstract

The pricing for immunologic agents and antibody-based therapeutics has increased precipitously in recent years. Among the key contributors to price hikes is the static practice of granting commercial exclusivity to innovator drugs and biologics. Herein, we present a mechanism for individualizing periods of commercial exclusivity to control pricing for drugs and biologics.

American Journal of Immunology
Volume 15 No. 1, 2019, 19-21

DOI: https://doi.org/10.3844/ajisp.2019.19.21

Submitted On: 14 August 2019 Published On: 13 September 2019

How to Cite: Blase, C. M., Rouault, B. K., Zoller, M. B., Luff, J. V., Lerch, E. J., Lauterbachq, B. N., Brown, M. A., Storsberg, J. & Schmidt, C. (2019). Individualizing Periods of Commercial Exclusivity to Control Pricing for Drugs and Biologics. American Journal of Immunology, 15(1), 19-21. https://doi.org/10.3844/ajisp.2019.19.21

Open AccessCopyright: © 2019 Callie M. Blase, Brandon K. Rouault, Maia B. Zoller, Joshua V. Luff, Emma J. Lerch, Brynn N. Lauterbachq, Mark A. Brown, Joachim Storsberg and Christian Schmidt. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

  • 3,885 Views
  • 1,902 Downloads
  • 0 Citations

Download

Keywords

  • Commercial Exclusivity
  • FDA
  • Immunologic Agents
  • Antibody-based Therapeutics